

CITATION REPORT

List of articles citing

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

DOI: 10.1038/ng.2521

Nature Genetics, 2013, 45, 164-71.

Source: <https://exaly.com/paper-pdf/55479331/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
798	Novel therapies for hepatitis C - one pill fits all?. 2013 , 12, 595-610		156
797	Impact of host and virus genome variability on HCV replication and response to interferon. 2013 , 3, 501-7		5
796	IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. 2013 , 65, 397-403		7
795	IL28B und antivirale Therapie der Virushepatitis: Was bleibt?. 2013 , 8, 322-329		
794	Single cell analysis of HCV-infected patient hepatocytes: the science is no longer science fiction. 2013 , 145, 1199-202		4
793	Immunology taught by human genetics. 2013 , 78, 157-72		48
792	Interferon-stimulated genes and their role in controlling hepatitis C virus. 2013 , 59, 1331-41		72
791	Interferon lambda 4 signals via the IFN λ receptor to regulate antiviral activity against HCV and coronaviruses. 2013 , 32, 3055-65		148
790	Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. 2013 , 20, 418-21		11
789	Monitoring the immune response to vaccination with an inactivated vaccine associated to bovine neonatal pancytopenia by deep sequencing transcriptome analysis in cattle. 2013 , 44, 93		18
788	Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells. 2013 , 64, 577-83		10
787	Hepatitis C virus: standard-of-care treatment. 2013 , 67, 169-215		41
786	Interferon induction and function at the mucosal surface. 2013 , 255, 25-39		153
785	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. 2013 , 12, 200-213		4
784	Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. 2013 , 59, 957-63		3
783	EASL recognition awardee 2013: Dr. Didier Lebrech. 2013 , 59, 405-7		0
782	Population genetic tools for dissecting innate immunity in humans. 2013 , 13, 280-93		87

781	Innate immune responses to hepatitis C virus. 2013 , 369, 219-42	34
780	Loss of function of the new interferon IFN- λ may confer protection from hepatitis C. <i>Nature Genetics</i> , 2013 , 45, 119-20	36.3 32
779	Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. 2013 , 58, 439-41	8
778	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. 2013 , 58, 1548-57	89
777	The genetic theory of infectious diseases: a brief history and selected illustrations. 2013 , 14, 215-43	98
776	Hepatitis: New gene IFNL4 is associated with impaired clearance of HCV. 2013 , 10, 63	7
775	Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. 2013 , 19, 859-68	328
774	Regulation of hepatic innate immunity by hepatitis C virus. 2013 , 19, 879-88	214
773	25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. 2013 , 13, 535-42	112
772	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 2013 , 210, 1109-16	179
771	Metabolic factors and chronic hepatitis C: a complex interplay. 2013 , 2013, 564645	23
770	Interferon- λ (IFNL4) transcript expression in human liver tissue samples. 2013 , 8, e84026	45
769	RNA-Seq and Human Complex Disease. 2013 ,	0
768	Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. 2013 , 27, 2817-9	11
767	Telaprevir is effective given every 12 h at 750 mg with pegylated interferon- α 2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. 2014 , 19, 277-85	12
766	Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis?. 2013 , 19, 6957-61	9
765	Targeted induction of interferon- α 1n humanized chimeric mouse liver abrogates hepatotropic virus infection. 2013 , 8, e59611	32
764	A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF- κ B-mediated gene transcription. 2013 , 8, e75495	20

763	Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. 2013 , 8, e77530	7
762	Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. 2013 , 8, e80003	8
761	Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. 2013 , 8, e80304	22
760	HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. 2013 , 8, e84226	27
759	Human but not mouse hepatocytes respond to interferon-lambda in vivo. 2014 , 9, e87906	38
758	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. 2014 , 9, e95515	20
757	The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. 2014 , 28, 481-7	6
756	Antiviral herbs--present and future. 2014 , 14, 61-73	22
755	Clinical utility of pharmacogenomics in the management of hepatitis C. 2014 , 7, 339-47	2
754	Interferon lambda induces antiviral response to herpes simplex virus 1 infection. 2014 , 58, 325-32	4
753	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. 2014 , 5,	1
752	Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response. 2014 , 4, 11-20	1
751	Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. 2014 , 15, 104	4
750	Pharmacogenomics of antimicrobial agents. 2014 , 15, 1903-30	18
749	Post-transcriptional regulation of interferons and their signaling pathways. 2014 , 34, 318-29	38
748	Hepatitis C Virus. Strategies to Evade Antiviral Responses. 2014 , 9, 1061-1075	26
747	Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 2014 , 2014, 710642	10
746	Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. 2014 , 5, 526	37

745	Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. 2014 , 88, 6394-402	28
744	Study on the IFNL4 gene ss469415590 variant in Ukrainian population. 2014 , 30, 400-402	2
743	Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). 2014 , 10, e1004681	66
742	Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. 2014 , 1, ofu110	44
741	Protective immunity against hepatitis C: many shades of gray. 2014 , 5, 274	65
740	The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. 2014 , 14, e22649	21
739	Interferon induction by RNA viruses and antagonism by viral pathogens. 2014 , 6, 4999-5027	40
738	Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. 2014 , 5, 545	16
737	IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfecting patients. 2014 , 28, 133-6	30
736	HIV-1 Tat clade-specific cytokine induction in monocytes/macrophages is not evidenced in total or VβVβ T lymphocytes. 2014 , 28, 131-3	1
735	[Hepatitis B and C: from molecular virology to new antiviral therapies (part 2)]. 2014 , 139, 778-82	0
734	P17: Role of interferon lambda-4 and inosine triphosphatase polymorphisms in the treatment of Thai patients with chronic hepatitis C virus genotype 3. 2014 , 21, 30-31	
733	Variation in genes encoding for interferon β and λ in the prediction of HCV-1 treatment-induced viral clearance. 2014 , 34, 1369-77	7
732	Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. 2014 , 59, 2423-4	2
731	Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients. 2014 , 83, 45-8	10
730	Polymorphisms of interferon-λ and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. 2014 , 39, 104-11	50
729	Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohort. 2014 , 38, 720-6	1
728	Interferons in the central nervous system: a few instruments play many tunes. 2014 , 62, 339-55	73

727	Letter: the irony of oral iron - not an underdog for post-gastrointestinal bleeding anaemia. 2014 , 39, 550-1	1
726	Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?. 2014 , 34, 964	4
725	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan. 2014 , 86, 1877-85	4
724	The interaction of a single-nucleotide polymorphism with age on response to interferon- α and ribavirin therapy in female patients with hepatitis C infection. 2014 , 86, 1130-3	
723	Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks?. 2014 , 39, 548-9	1
722	Reply: To PMID 23873583. 2014 , 59, 2424	
721	Innate and adaptive immune responses in HCV infections. 2014 , 61, S14-25	183
720	Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. 2014 , 21, e19-28	8
719	Association analysis of polymorphisms in OAS1 with susceptibility and severity of hand, foot and mouth disease. 2014 , 41, 384-92	13
718	Reduced IFN α activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. 2014 , 5, 5699	95
717	Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. 2014 , 21, 696-705	16
716	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. 2014 , 86, 1314-22	19
715	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. 2014 , 15, 16-24	15
714	In vitro blood cell responsiveness to IFN- α predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. 2014 , 12, 206	4
713	Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. 2014 , 1, 013	10
712	Update on primary sclerosing cholangitis genetics. 2014 , 30, 310-9	21
711	The HCV life cycle: in vitro tissue culture systems and therapeutic targets. 2014 , 32, 525-37	22
710	Predictors of hepatitis C treatment response: what's new?. 2014 , 12, 183-91	2

709	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. 2014 , 2014, 723868	9
708	The IFNL3/4 Δ variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. 2014 , 28, 1885-9	34
707	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 2014 , 106, 105-10	9
706	Kinetic differences in the induction of interferon stimulated genes by interferon- α and interleukin 28B are altered by infection with hepatitis C virus. 2014 , 59, 1250-61	75
705	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. 2014 , 44, E447-54	12
704	Hepatitis C virus: a silent killer relevant to dentistry. 2014 , 20, 425-9	2
703	IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. 2014 , 95, 1297-1306	11
702	Role of IL28B for chronic hepatitis C treatment toward personalized medicine. 2014 , 29, 241-9	38
701	Activation and evasion of antiviral innate immunity by hepatitis C virus. 2014 , 426, 1198-209	53
700	Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. 2014 , 101, 37-44	6
699	Acute hepatitis C: management in the rapidly evolving world of HCV. 2014 , 16, 371	14
698	The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. 2014 , 39, 322-30	20
697	Murine models of hepatitis C: what can we look forward to?. 2014 , 104, 15-22	26
696	Emerging therapies for the treatment of hepatitis C. 2014 , 6, 4-15	75
695	Interferon-stimulated genes: a complex web of host defenses. 2014 , 32, 513-45	1593
694	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfecting patients. 2014 , 60, 477-86	9
693	Hepatitis C Virus. 2014 , 859-877	
692	Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. 2014 , 15, 190-202	82

691	Review article: genetic factors that modify the outcome of viral hepatitis. 2014 , 39, 1059-70	42
690	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. 2014 , 59, 828-38	34
689	IFN- λ : the paradoxical new member of the interferon lambda family. 2014 , 34, 829-38	103
688	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. 2014 , 61, 235-41	33
687	HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. 2014 , 60, 1170-9	52
686	Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 2014 , 18, 25-38	1
685	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. 2014 , 49, 1548-56	18
684	Regulation of interferon lambda-1 (IFNL1/IFN- λ /IL-29) expression in human colon epithelial cells. 2014 , 65, 17-23	15
683	Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. 2014 , 209, 1907-15	21
682	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. 2014 , 146, 430-41.e6	193
681	Immune responses to HCV and other hepatitis viruses. 2014 , 40, 13-24	193
680	IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. 2014 , 20, 598-605	15
679	IFNL4- λ genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. 2014 , 209, 1700-4	71
678	Association of the IFNL4- λ Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. 2014 , 209, 350-4	75
677	Predictors of the therapeutic response in hepatitis C. A 2013 update. 2014 , 38, 12-7	5
676	Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg?. 2014 , 33, 60-3	9
675	Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. 2014 , 39, 343	10
674	IFNL cytokines do not modulate human or murine NK cell functions. 2014 , 75, 996-1000	17

673	High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815. 2014 , 20, O936-8	2
672	Genetic analysis of reproductive traits and antibody response in a PRRS outbreak herd. 2014 , 92, 2905-21	49
671	The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 2014 , 15, 72-9	119
670	Dynamics of HCV RNA levels during acute hepatitis C virus infection. 2014 , 86, 1722-9	21
669	Recent advances in the anti-HCV mechanisms of interferon. 2014 , 4, 241-7	20
668	IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. 2014 , 86, 1482-90	20
667	Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated. 2014 , 12, 1082-7	0
666	The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. 2014 , 3, e51	109
665	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. 2014 , 61, 282-5	3
664	Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent. 2014 , 15, 241-6	4
663	Does the interferon-lambda rather than the interferon-alpha pathway determine the outcome of hepatitis C virus infection?. 2014 , 60, 1437-9	
662	Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. 2014 , 143, 319-30	13
661	The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. 2014 , 30, 72-8	17
660	Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. 2014 , 21, 397-404	10
659	Endogenous IFN λ in viral hepatitis patients. 2014 , 34, 552-6	6
658	Antiviral treatment of hepatitis C. 2014 , 348, g3308	154
657	Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. 2014 , 59, 2424-5	29
656	Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. 2014 , 15, 349-70	104

655	Hepatitis C virus and interferon type III (interferon- β /interleukin-28B and interferon- λ): genetic basis of susceptibility to infection and response to antiviral treatment. 2014 , 20, 1237-45	12
654	IFN- λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN- β genotype and with nonresponsiveness to IFN- λ therapies. 2014 , 211, 857-68	54
653	Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 T allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. 2014 , 59, 274-5	10
652	Type III interferons are expressed by Cocksackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. 2014 , 177, 687-95	14
651	Immune control and failure in HCV infection--tipping the balance. 2014 , 96, 535-48	33
650	Deep sequencing: becoming a critical tool in clinical virology. 2014 , 61, 9-19	98
649	[The value of genetics in the era of hepatitis C triple therapy]. 2014 , 37, 427-37	2
648	Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? Authors' reply. 2014 , 39, 549-50	1
647	Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. 2014 , 34, 479-97	12
646	Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3. 2014 , 86, 707-12	11
645	Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. 2014 , 59, 1225-8	17
644	Regulation of the catabolic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis. 2014 , 156, 730-43	229
643	HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. 2014 , 61, 730-7	19
642	Reply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools". 2014 , 61, 179-80	
641	Role of genetics in diagnosis and therapy of acquired liver disease. 2014 , 37, 15-34	5
640	The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?. 2014 , 105, 32-8	25
639	Type I and III interferon production in response to RNA viruses. 2014 , 34, 649-58	18
638	MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. 2014 , 21, 99-110	31

637	Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. 2014 , 61, 770-6	9
636	A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses. 2014 , 147, e1-4	9
635	Interferon- β in the context of viral infections: production, response and therapeutic implications. 2014 , 6, 563-74	79
634	Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. 2014 , 124, 3352-63	148
633	The bacterial pathogen <i>Listeria monocytogenes</i> and the interferon family: type I, type II and type III interferons. 2014 , 4, 50	58
632	Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. 2014 , 20, 2927-40	38
631	IL28B genotyping and treatment of HCV infected subjects. 2014 , 8, 445-452	
630	IFNL3 expression and response to treatment: behind the HCV tricks. 2014 , 61, 944-6	
629	Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. 2015 , 35, 402-20	17
628	Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System. 2015 , 82, 199-207	71
627	The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. 2015 , 86, 267-75	9
626	Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis. 2015 , 1-29	
625	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. 2015 , 163, 899-907	46
624	Variants in Antiviral Genes are Risk Factors for Cognitive Decline and Dementia. 2015 , 46, 655-63	12
623	IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. 2015 , 5, 16037	37
622	PharmGKB summary: peginterferon- β pathway. 2015 , 25, 465-74	
621	Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. 2015 , 5, 17030	23
620	Hard Work Ahead: Fine Mapping and Functional Follow-up of Susceptibility Alleles in Cancer GWAS. 2015 , 2, 205-217	1

619	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. 2015 , 35, 1833-44	5
618	Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. 2015 , 123, 765-71	5
617	IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes. 2015 , 20, 805-14	2
616	A case of hepatocellular carcinoma after achieving sustained virologic response treated with asunaprevir/daclatasvir in chronic hepatitis C virus infection. 2015 , 56, 348-355	1
615	Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women. 2015 , 22, 1055-60	3
614	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. 2015 , 29, 1895-7	17
613	IFNL4 gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. 2015 , 87, 1702-15	7
612	The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. 2015 , 42, 296-306	11
611	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. 2015 , 22, 1020-32	7
610	Time of HIV diagnosis in infants after weaning from breast milk. 2015 , 29, 1897-8	2
609	USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study. 2015 , 11, 1853-61	2
608	Hepatitis C. 2015 , 1904-1927.e9	4
607	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. 2015 , 7, 3995-4046	38
606	Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection. 2015 , 16, 23683-94	3
605	NK cell function and receptor diversity in the context of HCV infection. 2015 , 6, 1061	23
604	Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment. 2015 , 2, ofv091	5
603	Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses. 2015 , 7, 3675-702	19
602	IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. 2015 , 10, e0117397	10

601	Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. 2015 , 10, e0125400	7
600	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. 2015 , 10, e0138827	5
599	IFN- λ Inhibits MiR-122 Transcription through a Stat3-HNF4 α Inflammatory Feedback Loop in an IFN- λ Resistant HCV Cell Culture System. 2015 , 10, e0141655	10
598	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. 2015 , 10, e0142539	7
597	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. 2015 , 10, e0145622	2
596	Activation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus. 2015 , 11, e1005264	91
595	Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2'-O-Methylation Mutant. 2015 , 11, e1005345	35
594	IFN- λ A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. 2015 , 2015, 796461	7
593	An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. 2015 , 29, 19-34	59
592	Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis. 2015 , 15, e32707	5
591	Viral Hepatitis. 2015 , 1439-1468.e7	4
590	Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?. 2015 , 21, 3786-800	18
589	Influence of host resistance on viral adaptation: hepatitis C virus as a case study. 2015 , 8, 63-74	4
588	Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. 2015 , 16, 321-9	21
587	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. 2015 , 98, 283-94	9
586	Interferon lambda inhibits dengue virus replication in epithelial cells. 2015 , 12, 150	39
585	Effect of IL28B genotype on hepatitis B and C virus infection. 2015 , 14, 50-5	17
584	Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. 2015 , 26, 121-31	35

583	IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. 2015 , 87, 814-20	10
582	Hepatitis C. 2015 , 385, 1124-35	365
581	Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. 2015 , 160, 1105-12	6
580	Type I interferons in infectious disease. 2015 , 15, 87-103	1131
579	Impaired induction of interleukin 28B and expression of interferon λ associated with nonresponse to interferon-based therapy in chronic hepatitis C. 2015 , 30, 1075-84	14
578	Interferon- λ is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. 2015 , 476, 334-340	30
577	Innate and adaptive genetic pathways in HCV infection. 2015 , 85, 231-40	11
576	The Role of Interferon- λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. 2015 , 7, 231-42	22
575	Interferons and viruses: an evolutionary arms race of molecular interactions. 2015 , 36, 124-38	243
574	Activation of Type I and Type III Interferons in Chronic Hepatitis C. 2015 , 7, 251-259	13
573	Resistance to hepatitis C virus: potential genetic and immunological determinants. 2015 , 15, 451-60	16
572	Transcriptome analysis reveals a classical interferon signature induced by IFN λ in human primary cells. 2015 , 16, 414-21	31
571	Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. 2015 , 61, 1381-8	27
570	A genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infection. 2015 , 46, 448-53	8
569	Interferon λ and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. 2015 , 17, 583-9	1
568	Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells. 2015 , 35, 888-900	27
567	Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection. 2015 , 16, 3213-25	1
566	Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aborigines in Canadian HIV-hepatitis C co-infected individuals. 2015 , 16, 6496-512	5

565	The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. 2015 , 60, 2232-5	1
564	Advanced molecular surveillance of hepatitis C virus. 2015 , 7, 1153-88	9
563	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. 2015 , 63, 1103-10	52
562	Interferon- λ Immune Functions at Barrier Surfaces and Beyond. 2015 , 43, 15-28	280
561	Guarding the frontiers: the biology of type III interferons. 2015 , 16, 802-9	212
560	HIV-1 and interferons: who's interfering with whom?. 2015 , 13, 403-13	193
559	From non-A, non-B hepatitis to hepatitis C virus cure. 2015 , 62, S87-99	231
558	NK cells require IL-28R for optimal in vivo activity. 2015 , 112, E2376-84	64
557	Genetics of liver disease: From pathophysiology to clinical practice. 2015 , 62, S6-S14	58
556	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. 2015 , 22, 708-17	13
555	The correlation between hepatitis C core antigen and hepatitis C virus RNA levels with respect to human immunodeficiency virus status, hepatitis C virus genotype and interferon-lambda-4 polymorphism. 2015 , 58, 73-9	8
554	Antiviral Effect of Interferon Lambda Against Lymphocytic Choriomeningitis Virus. 2015 , 35, 540-53	7
553	The unique regulation and functions of type III interferons in antiviral immunity. 2015 , 12, 47-52	59
552	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. 2015 , 9, 251-7	13
551	Interferon- λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. 2015 , 6, 6422	127
550	Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. 2015 , 35, 2256-64	9
549	Insights into antiviral innate immunity revealed by studying hepatitis C virus. 2015 , 74, 190-7	5
548	Regulation of antiviral T cell responses by type I interferons. 2015 , 15, 231-42	256

547	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. 2015 , 313, 1232-9	171
546	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. 2015 , 63, 554-63	20
545	No Love Lost Between Viruses and Interferons. 2015 , 2, 549-72	89
544	Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population. 2015 , 16, 514-8	7
543	Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. 2015 , 8, 260	7
542	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. 2015 , 16, 1179-88	15
541	The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. 2015 , 13, 544-58	26
540	CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population. 2015 , 35, 786-94	4
539	Natural History of Hepatitis C. 2015 , 44, 717-34	121
538	Immunopathogenesis of Hepatitis C Virus Infection. 2015 , 44, 735-60	9
537	IFN α stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. 2015 , 135, 2935-2943	16
536	Type III interferons (IFNs): Emerging Master Regulators of Immunity. 2015 , 850, 1-15	26
535	The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. 2015 , 62, 1024-32	21
534	IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. 2015 , 21, 289.e1-4	18
533	Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. 2015 , 211, 906-14	50
532	T cell responses in hepatitis C virus infection: historical overview and goals for future research. 2015 , 114, 96-105	34
531	Impact and regulation of lambda interferon response in human metapneumovirus infection. 2015 , 89, 730-42	39
530	Increased concentration of interferon lambda-3, interferon beta and interleukin-10 in the cerebrospinal fluid of patients with tick-borne encephalitis. 2015 , 71, 125-31	15

529	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. 2015 , 61, 712-21	114
528	Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages. 2015 , 35, 213-21	14
527	Homozygosity for HLA group 2 alleles predicts treatment failure with interferon- α and ribavirin in chronic hepatitis C virus genotype 1 infection. 2015 , 35, 126-33	4
526	The Role of Interferons on the Central Nervous System in Health and Disease?. 2016 ,	1
525	Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes. 2016 , 10, 163-82	7
524	Interferon lambda 4 (IFNL4) gene polymorphism is associated with spontaneous clearance of HCV in HIV-1 positive patients. 2016 , 39, 374-9	6
523	IFN- α New Inducer of Local Immunity against Cancer and Infections. 2016 , 7, 598	14
522	Type III Interferons in Hepatitis C Virus Infection. 2016 , 7, 628	23
521	Mumps Virus Induces Protein-Kinase-R-Dependent Stress Granules, Partly Suppressing Type III Interferon Production. 2016 , 11, e0161793	6
520	Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. 2016 , 11, e0147007	1
519	IL-28B Genetic Variants Determine the Extent of Monocyte-Induced Activation of NK Cells in Hepatitis C. 2016 , 11, e0162068	4
518	The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors. 2016 , 11, e0163900	15
517	Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. 2016 , 15, 17-26	7
516	ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. 2016 , 7, 74393-74409	27
515	Host genetic variants influencing the clinical course of hepatitis C virus infection. 2016 , 88, 185-95	26
514	Innate immunity against hepatitis C virus. 2016 , 42, 98-104	25
513	Immune responses and immunopathology in acute and chronic viral hepatitis. 2016 , 16, 509-23	176
512	Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women. 2016 , 72, 162-70	10

511	Genetic variation in STAT4 predicts response to interferon- β therapy for hepatitis B e antigen-positive chronic hepatitis B. 2016 , 63, 1102-11	20
510	Hepatitis C-A clinical review. 2016 , 88, 1844-55	27
509	Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. 2016 , 23, 340-7	1
508	Implications of Pharmacogenetics for Antimicrobial Prescribing. 2016 , 613-633	
507	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. 2017 , 64, 621-628	26
506	IFN- β polymorphism indirectly influences NK cell phenotype and function during acute HCV infection. 2016 , 4, 376-88	3
505	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. 2016 , 90, 5549-5560	22
504	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. 2016 , 63, 63-73	37
503	The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. 2016 , 291, 12294-309	20
502	Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis. 2016 , 77, 609-15	4
501	Immune evasion of porcine enteric coronaviruses and viral modulation of antiviral innate signaling. 2016 , 226, 128-141	58
500	Experimental models of hepatitis B and C - new insights and progress. 2016 , 13, 362-74	52
499	Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. 2016 , 493, 136-41	7
498	Evolution of IFN- γ in tetrapod vertebrates and its functional characterization in green anole lizard (<i>Anolis carolinensis</i>). 2016 , 61, 208-24	22
497	Genetics in Common Liver Diseases: From Pathophysiology to Precise Treatment. 2016 , 34, 391-5	2
496	Prolonged activation of innate antiviral gene signature after childbirth is determined by IFNL3 genotype. 2016 , 113, 10678-83	21
495	Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. 2016 , 113, 10684-9	16
494	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. 2016 , 161, 3263-8	2

493	Poster Presentations. 2016 , 87, 58-160	78
492	Targeting IFN- λ therapeutic implications. 2016 , 20, 1425-1432	12
491	Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. 2016 , 20, 1-10	32
490	A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance. 2016 , 43, 1101-17	4
489	Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β and TNF- β Receptors, functions, and roles in diseases. 2016 , 138, 984-1010	391
488	Soluble IL-6 Receptor and IL-27 Subunit p28 Protein Complex Mediate the Antiviral Response through the Type III IFN Pathway. 2016 , 197, 2369-81	10
487	Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN- λ or IL-29/IFN- λ . 2016 , 23, 266-77	8
486	Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. 2016 , 161, 3161-9	21
485	Population Polymorphism of IFNL3 and IFNL4 Genes of Type 3 Interferon Associated with Spontaneous Clearance of Hepatitis C Virus in Representatives of Caucasian and Mongoloid Races. 2016 , 161, 404-7	2
484	Host - hepatitis C viral interactions: The role of genetics. 2016 , 65, S22-S32	42
483	Early treatment with reverse transcriptase inhibitors significantly suppresses peak plasma IFN λ vivo during acute simian immunodeficiency virus infection. 2016 , 310, 156-164	7
482	Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. 2016 , 23, 496-505	31
481	Interferon λ 2016 , 485-493	0
480	IFN- λ cancer immunotherapy: new kid on the block. 2016 , 8, 877-88	21
479	New Interferons. 2016 , 501-508	1
478	polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients. 2016 , 50, 330-333	1
477	Genetic variations of the NPC1L1 gene associated with hepatitis C virus (HCV) infection and biochemical characteristics of HCV patients in China. 2016 , 53, 6-11	7
476	Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis. 2016 , 53, 52-58	7

475	Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 2016 , 22, 1475-1481	26
474	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. 2016 , 225-241	
473	Combination of Adt-O1Manisa and Ad5-boIFN β induces early protective immunity against foot-and-mouth disease in cattle. 2016 , 499, 340-349	13
472	Hepatitis C Virus II. 2016 ,	1
471	Interferon lambda 4 expression is suppressed by the host during viral infection. 2016 , 213, 2539-2552	43
470	Hepatitis C Virus I. 2016 ,	2
469	The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. 2016 , 169, 156-162	10
468	Organ system view of the hepatic innate immunity in HCV infection. 2016 , 88, 2025-2037	9
467	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. 2016 , 46, 1256-1263	6
466	Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections. 2016 , 17, 265-75	13
465	Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection. 2016 , 214, 739-47	9
464	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. 2016 , 17, 328-34	8
463	Murine gammaherpesvirus targets type I IFN receptor but not type III IFN receptor early in infection. 2016 , 83, 158-170	5
462	Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. 2016 , 214, 80-6	9
461	IFN-lambda therapy: current status and future perspectives. 2016 , 21, 167-171	18
460	Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil. 2016 , 161, 1477-84	10
459	The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. 2016 , 29, 71-81	73
458	Microbial pathogenesis and type III interferons. 2016 , 29, 45-51	12

457	Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon- λ Expression. 2016 , 186, 938-51	10
456	IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. 2016 , 39, 132-140	7
455	Roles for Transcription Factors Sp1, NF- κ B, IRF3, and IRF7 in Expression of the Human IFNL4 Gene. 2016 , 29, 49-63	6
454	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. 2016 , 64, 301-307	125
453	Type I, II, and III Interferons: Regulating Immunity to Mycobacterium tuberculosis Infection. 2016 , 64, 19-31	24
452	Comparative Functional Analysis of 12 Mammalian IFN- λ Orthologs. 2016 , 36, 30-6	11
451	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN- λ 2017 , 66, 724-735	46
450	Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. 2017 , 17, 225-232	7
449	IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. 2017 , 47, E5-E13	4
448	Association of DDX58 177 C > T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma. 2017 , 58, 438-444	0
447	Race or genetic makeup for hepatitis C virus treatment decisions?. 2017 , 65, 2124-2125	14
446	A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. 2017 , 445, 15-22	2
445	Magnolol and honokiol from Magnolia officinalis enhanced antiviral immune responses against grass carp reovirus in Ctenopharyngodon idella kidney cells. 2017 , 63, 245-254	44
444	A systematic review and meta-analysis of HCV clearance. 2017 , 37, 1431-1445	24
443	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. 2017 , 66, 1829-1837	17
442	Genetic variants in interferon- λ influences HCV clearance in Chinese Han population. 2017 , 7, 42408	4
441	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017 , 49, 666-673	36.3 81
440	IFN- λ , not IFN- β , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3 72

439	Identification of Type III Interferon (IFN- λ) in Chinese Goose: Gene Structure, Age-Dependent Expression Profile, and Antiviral Immune Characteristics In Vivo and In Vitro. 2017 , 37, 269-277	2
438	Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver. 2017 , 9, 816-834	28
437	SCARB1 variants and HCV infection: Host susceptibility is lost in translation. 2017 , 67, 211-213	
436	Interferon- λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. 2017 , 46, 875-890.e6	256
435	Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B. 2017 , 22, 681-688	9
434	Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication. 2017 , 37, 1-16	21
433	Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses. 2017 , 206, 45-51	72
432	Zinc is a potent and specific inhibitor of IFN- β signalling. 2017 , 8, 15245	38
431	IFN- λ potently blocks IFN- β signalling by ISG15 and USP18 in hepatitis C virus infection. 2017 , 7, 3821	17
430	Genetik metabolischer und viraler Lebererkrankungen. 2017 , 12, 16-31	0
429	Immunopathology in Toxicology and Drug Development. 2017 ,	0
428	Rhinovirus species/genotypes and interferon- λ subtypes, receptor and polymorphisms - missing pieces of the puzzle of childhood asthma?. 2017 , 49,	
427	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. 2017 , 67, 237-245	20
426	Contribution of type III interferons to antiviral immunity: location, location, location. 2017 , 292, 7295-7303	65
425	Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. 2017 , 89, 1241-1247	7
424	Evaluation of HTLV-1 HBZ and proviral load, together with host IFN β , in pathogenesis of HAM/TSP. 2017 , 89, 1102-1107	5
423	A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C. 2017 , 48, 51-56	6
422	Comparison of approaches for incorporating new information into existing risk prediction models. 2017 , 36, 1134-1156	10

421	IFN- λ Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. 2017 , 199, 3808-3820	42
420	Hepatitis C and the Impact of Host Genetics. 2017 , 19, 805-808	
419	Serum IFN- β Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. 2017 , 35, 531-540	1
418	Human Genetic Determinants of Viral Diseases. 2017 , 51, 241-263	68
417	SOCS1 is an inducible negative regulator of interferon α (IFN- α) induced gene expression. 2017 , 292, 17928-17938	33
416	Type III Interferons in Systemic Lupus Erythematosus: Association Between Interferon β , Disease Activity, and Anti-Ro/SSA Antibodies. 2017 , 23, 368-375	17
415	Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. 2017 , 19, 857-869	4
414	A functional IFN- λ -generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma. 2017 , 7, 10500	5
413	Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon- α /Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection. 2017 , 37, 369-382	6
412	Interferon lambda 4 rs368234815 TT>C variant is associated with liver damage in patients with nonalcoholic fatty liver disease. 2017 , 66, 1885-1893	59
411	The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. 2017 , 54, 330-337	15
410	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. 2017 , 7, 15843	3
409	IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir. 2017 , 153, 1694-1695	16
408	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. 2017 , 89, 1963-1972	10
407	Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. 2017 , 30, 23-42	7
406	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. 2017 , 32, 645-650	11
405	Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. 2017 , 89, 388-396	9
404	Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon- α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. 2017 , 31,	13

403	IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review. 2017 , 17, 281-289	13
402	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. 2017 , 52, 504-511	14
401	Hepatitis C. 2017 , 628-698	
400	Search for genetic markers of climatic adaptation in populations of North Eurasia. 2017 , 53, 1172-1183	6
399	The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection. 2017 , 35, 262-268	4
398	Approaches and Considerations for the Successful Treatment of HCV Infection. 2017 ,	
397	IFN- λ A Contentious Player in Host-Pathogen Interaction in Tuberculosis. 2017 , 18,	8
396	Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. 2017 , 5,	29
395	Interferon Lambda: Modulating Immunity in Infectious Diseases. 2017 , 8, 119	84
394	Type I Interferons as Regulators of Lung Inflammation. 2017 , 8, 259	85
393	Type I and Type III Interferons Display Different Dependency on Mitogen-Activated Protein Kinases to Mount an Antiviral State in the Human Gut. 2017 , 8, 459	58
392	Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. 2017 , 8, 749	42
391	Interferon- β and Plasmacytoid Dendritic Cells: A Close Relationship. 2017 , 8, 1015	13
390	Interferon- β : Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract. 2017 , 8, 1232	45
389	Interferon Lambda Genetics and Biology in Regulation of Viral Control. 2017 , 8, 1707	66
388	Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism. 2017 , 8, 1758	68
387	Lambda-Interferons Inhibit Herpes Simplex Virus Type 2 Replication in Human Cervical Epithelial Cells by Activating the JAK/STAT Pathway. 2017 , 70, 416-422	
386	The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. 2017 , 2017, 7232361	17

385	Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C. 2017 , 12, e0179094	1
384	Comparison of transcriptional profiles of interferons, CXCL10 and RIG-1 in influenza infected A549 cells stimulated with exogenous interferons. 2017 , 61, 183-190	2
383	Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. 2017 , 10, 79-91	2
382	STING-Dependent Interferon- β Induction in HT29 Cells, a Human Colorectal Cancer Cell Line, After Gamma-Radiation. 2018 , 101, 97-106	11
381	Alcohol attenuates anti-HCV function of IFN- β through up-regulation of PLASy expression in human hepatic cells. 2018 , 90, 1112-1120	2
380	Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. 2018 , 217, 650-655	14
379	Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population. 2018 , 146, 379-385	1
378	Genetic Association Studies in Host-Pathogen Interaction Analysis. 2018 , 1734, 1-11	
377	Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome. 2018 , 54, 319-322	2
376	Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. 2018 , 68, 2078-2088	26
375	Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN- λ . 2018 , 664, 168-180	7
374	Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance. 2018 , 63, 831-839	
373	Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. 2018 , 40, 19-31	21
372	Analysis of the expression patterns of the cytokine receptor family B (CRFB) and interferon gamma receptor (IFNGR) in Dabry's sturgeon (<i>Acipenser dabryanus</i>). 2018 , 84, 420-426	18
371	How Does Vaccinia Virus Interfere With Interferon?. 2018 , 100, 355-378	26
370	Induction of IFN- β as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. 2018 , 67, 362-371	93
369	Beneficial Role of Citrus Fruit Polyphenols Against Hepatic Dysfunctions: A Review. 2018 , 15, 223-250	10
368	IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBSAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients. 2018 , 38, 417-423	7

- 367 Meeting summary: 2nd Aegean Conference on Cytokine Signaling in Cancer. **2018**, 108, 225-231
- 366 Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population. **2018**, 25, 306-313 12
- 365 Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches. **2018**, 66, 286-307 25
- 364 Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. **2018**, 163, 115-124 2
- 363 Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers. **2018**, 66, 106-111 1
- 362 Host genetic variations associated with disease progression in chronic hepatitis C virus infection. **2018**, 48, 127-133 14
- 361 Type III Interferon Restriction by Porcine Epidemic Diarrhea Virus and the Role of Viral Protein nsp1 in IRF1 Signaling. **2018**, 92, 67
- 360 Targeting interferons and their pathways in systemic lupus erythematosus. **2018**, 17, 44-52 80
- 359 The role of genetics in hepatic fibrosis among hepatitis C virus patients. **2018**, 67, 2043-2045 5
- 358 The Role of Interferon in Persistent Viral Infection: Insights from Murine Norovirus. **2018**, 26, 510-524 23
- 357 Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. **2018**, 66, 376-391 7
- 356 Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome. **2018**, 31, 593-597 1
- 355 Nonalcoholic fatty liver disease: is the IFNL4 rs368234815 variant protective from liver damage?. **2018**, 7, 209-211
- 354 Virology and Pathogenesis of Hepatitis C. **2018**, 412-427.e8
- 353 Hepatitis C: Host and Viral Factors Associated with Response to Therapy and Progression of Liver Fibrosis. **2018**, 0
- 352 Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. **2018**, 32, 2759-2765 5
- 351 Type III Interferons in Viral Infection and Antiviral Immunity. **2018**, 51, 173-185 67
- 350 -1 is associated with prostate cancer among men at increased risk of sexually transmitted infections. **2018**, 1, 191 20

349	[Interferon Lambda 4 RS12979860 C>T polymorphism is not associated with liver fibrosis in patients with hepatitis C]. 2018 , 146, 823-829	1
348	IFN- λ inhibits HIV infection of macrophages through signalling of IFN-R1/IL-10R2 receptor complex. 2018 , 88, e12717	5
347	Impact of the Uridine?Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. 2018 , 54,	2
346	Variation in the Untranslated Genome and Susceptibility to Infections. 2018 , 9, 2046	10
345	Cellular Inflammatory Responses. 2018 , 475-590	
344	A polymorphic residue that attenuates the antiviral potential of interferon lambda 4 in hominid lineages. 2018 , 14, e1007307	13
343	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. 2018 , 285, 55-71	8
342	Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon- λ 2018 , 38, 469-479	8
341	Biological determinants of health disparities in multiple myeloma. 2018 , 8, 85	18
340	Type III Interferons in Antiviral Defenses at Barrier Surfaces. 2018 , 39, 848-858	61
339	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. 2018 , 13, e0199198	4
338	Interferon- λ /4 genetic variants and interferon- λ serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. 2018 , 20, 193	22
337	Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of and Single Nucleotide Polymorphisms. 2018 , 2018, 2931486	2
336	Direct-acting antiviral treatment of acute hepatitis C virus infections. 2018 , 16, 599-610	3
335	Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. 2018 , 13, e0200221	5
334	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. 2018 , 19, 979-995	0
333	Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation. 2018 , 10,	11
332	- λ Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer. 2018 , 24, 5471-5481	30

331	Association of IFN λ rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. 2018 , 90, 1779-1783	4
330	Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. 2018 , 13, e0198296	2
329	Impact of IFNL4- Δ genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals. 2018 , 92, 34-36	3
328	ADAR1 affects HCV infection by modulating innate immune response. 2018 , 156, 116-127	17
327	IFN- β inhibit Hantaan virus infection through the JAK-STAT pathway and expression of Mx2 protein. 2019 , 20, 234-244	9
326	The role of IFN in the development of NAFLD and NASH. 2019 , 124, 154519	17
325	Interferon Lambda: Toward a Dual Role in Cancer. 2019 , 39, 22-29	15
324	Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1. 2019 , 93,	33
323	Type-Specific Crosstalk Modulates Interferon Signaling in Intestinal Epithelial Cells. 2019 , 39, 650-660	3
322	haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population. 2019 , 30, 344-353	
321	Genetic variants in RIG-I-like receptor influences HCV clearance in Chinese Han population. 2019 , 147, e195	3
320	Impact of Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. 2019 , 39, 642-649	4
319	The IFN- λ Conundrum: When a Good Interferon Goes Bad. 2019 , 39, 636-641	11
318	NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. 2019 , 8,	9
317	Manipulation of Mononuclear Phagocytes by HIV: Implications for Early Transmission Events. 2019 , 10, 2263	5
316	CCR5-B2 and IFNL4- Δ /TT. 2019 , 41, 2658-2659	
315	Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. 2019 , 8,	27
314	Host Genetic Determinants of Hepatitis B Virus Infection. 2019 , 10, 696	19

313	Disruption of Type III Interferon (IFN) Genes and Recapitulates Loss of the Type III IFN Receptor in the Mucosal Antiviral Response. 2019 , 93,	17
312	Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons. 2019 , 51, 451-464.e6	82
311	Lambda interferons in immunity and autoimmunity. 2019 , 104, 102319	11
310	Impact of CYP2R1, CYP27A1 and CYP27B1 genetic polymorphisms controlling vitamin D metabolism on susceptibility to hepatitis C virus infection in a high-risk Chinese population. 2019 , 164, 2909-2918	3
309	The Influence of the rs30461 Single Nucleotide Polymorphism on IFN- λ Activity and Secretion. 2019 , 39, 661-667	3
308	Interferon- λ modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus. 2019 , 20, 1035-1045	50
307	Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease. 2019 , 10, 1176	51
306	Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals. 2019 , 19, 401-406	9
305	What Have We Learned from Studies of IFN- λ Variants and Hepatitis C Virus Infection?. 2019 , 39, 618-626	2
304	IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period. 2019 , 21, e13124	3
303	Genetics of the Human Interferon Lambda Region. 2019 , 39, 599-608	21
302	Interferon Lambda and Liver Fibrosis. 2019 , 39, 627-635	6
301	Chicken viperin inhibits Newcastle disease virus infection in vitro: A possible interaction with the viral matrix protein. 2019 , 120, 28-40	12
300	Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential. 2019 , 39, 586-591	2
299	Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?. 2019 , 8,	19
298	Shared and Distinct Functions of Type I and Type III Interferons. 2019 , 50, 907-923	375
297	Interferon Lambda: An Immune System Factor That Cancer Epidemiologists Should Consider. 2019 , 39, 592-593	
296	Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. 2019 , 54, 916-927	17

295	Hierarchical assessment of host factors influencing the spontaneous resolution of hepatitis C infection. 2019 , 50, 147-155	
294	Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection. 2019 , 39, 133-146	2
293	Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?. 2019 , 49, 605-616	3
292	Differential Regulation of Type I and Type III Interferon Signaling. 2019 , 20,	78
291	Running interference: Interplay between Zika virus and the host interferon response. 2019 , 119, 7-15	9
290	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. 2019 , 156, 1496-1507.e7	20
289	Comparative host genomics: how has human evolution affected our immune defence against hepatitis C virus?. 2019 , 14, 125-128	1
288	Is the conquest of Hepatitis C imminent?. 2019 , 21, e3	1
287	Decoding type I and III interferon signalling during viral infection. 2019 , 4, 914-924	179
286	Npro of Classical Swine Fever Virus Suppresses Type III Interferon Production by Inhibiting IRF1 Expression and Its Nuclear Translocation. 2019 , 11,	3
285	Changes in Serum Levels of Type-III Interferons in Ankylosing Spondylitis Treated With Tumor Necrosis Factor-Alpha Inhibitors. 2019 , 34, 9-17	1
284	Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections. 2019 , 9, 340	17
283	Type III IFNs: Beyond antiviral protection. 2019 , 43, 101303	34
282	Viral hepatitis. 2019 , 155-165	
281	Association of rs12979860 polymorphism with HCV-related hepatocellular carcinoma susceptibility in a Chinese population. 2019 , 12, 433-439	2
280	Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients. 2019 , 91, 411-418	11
279	Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. 2019 , 156, 369-383	62
278	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. 2019 , 156, 400-417	21

277	Both type I and type III interferons are required to restrict measles virus growth in lung epithelial cells. 2019 , 164, 439-446	5
276	Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control. 2019 , 56, 67-75	42
275	Type I Interferons in NeuroHIV. 2019 , 32, 7-14	10
274	The Molecular Basis of Viral Inhibition of IRF- and STAT-Dependent Immune Responses. 2018 , 9, 3086	53
273	A Knockout IFNL4 Variant Is Associated With Protection From Sexually Transmitted HIV-1 Infection. 2019 , 219, 772-776	4
272	Innate Immunity to Enteric Hepatitis Viruses. 2019 , 9,	14
271	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. 2020 , 323-336.e3	1
270	Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4- τ and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. 2020 , 221, 102-109	3
269	Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency. 2020 , 125, 154833	6
268	Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. 2020 , 7, 392-400	8
267	Type III Interferons (Lambda Interferons) in Rheumatic Autoimmune Diseases. 2020 , 68, 1	7
266	Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms. 2020 , 79, 104144	2
265	IFNL4: Notable variants and associated phenotypes. 2020 , 730, 144289	9
264	SARS-CoV-2 infection in India bucks the trend: Trained innate immunity?. 2021 , 33, e23504	8
263	Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. <i>Nature Genetics</i> , 2020 , 52, 1283-1293	36.3 132
262	Comparative Transcriptomic and Proteomic Analyses Prove that IFN- β is a More Potent Inducer of ISGs than IFN- α against Porcine Epidemic Diarrhea Virus in Porcine Intestinal Epithelial Cells. 2020 , 19, 3697-3707	2
261	The Role of Structure in the Biology of Interferon Signaling. 2020 , 11, 606489	21
260	Interferon-lambda (IFNL) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data. 2020 , 20, 1131	1

259	The Key Roles of Interferon Lambda in Human Molecular Defense against Respiratory Viral Infections. 2020 , 9,	8
258	Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN- β or IFN- γ show distinct phenotypes. 2021 , 110, 357-374	6
257	Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. 2021 , 19, 2398-2406.e1	0
256	High-risk Allele for Herpes Labialis Severity at the IFNL3/4 Locus is Associated With Vestibular Neuritis. 2020 , 11, 570638	1
255	The Roles of Type I Interferon in Co-infections With Parasites and Viruses, Bacteria, or Other Parasites. 2020 , 11, 1805	1
254	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. 2020 , 55, 1162-1170	2
253	Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. 2020 , 86, 104606	0
252	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. 2020 , 21, 348-359	2
251	COVID-19 and emerging viral infections: The case for interferon lambda. 2020 , 217,	137
250	IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation. 2020 , 7, e698-e699	
249	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. 2020 , 7, e715-e723	4
248	Differential Induction of Type I and III Interferons by. 2020 , 88,	7
247	Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces. 2020 , 11, 608645	33
246	Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons. 2021 , 34, 307-320	13
245	mSphere of Influence: Interferon Ultra Is a Means To Fight Viral Disease. 2020 , 5,	
244	Lack of Association between IFNL3 Polymorphism and Human Papillomavirus Infection and Their Progression in HIV-Infected Women Receiving Antiretroviral Treatment. 2020 , 87, 262-267	
243	Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response. 2020 , 9,	17
242	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. 2020 , 69, 1659-1666	5

241	The presence of rs12979860 C allele influences the in vitro IP-10 production by mononuclear cells from patients with systemic lupus erythematosus. 2020 , 29, 482-489	4
240	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. 2020 , 5, 253-263	
239	Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. 2020 , 139, 855-863	5
238	Genetic and epigenetic regulation of natural resistance to HIV-1 infection: new approaches to unveil the HESN secret. 2020 , 16, 429-445	4
237	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. 2020 , 21,	7
236	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. 2020 , 9,	13
235	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection. 2020 , 868-888	
234	COVID-19: Possible Impact of the Genetic Background in IFNL Genes on Disease Outcomes. 2020 , 12, 273-274	7
233	Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital: A STROBE-complaint article. 2020 , 99, e19505	1
232	Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. 2020 , 16, e1008515	22
231	Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon- λ to Treat Early Coronavirus Disease 2019. 2020 , 71, 1410-1412	65
230	Polymorphism rs368234815 of interferon- λ gene and generation of antibodies to hepatitis B virus surface antigen in extracorporeal dialysis patients. 2020 , 19, 293-303	4
229	The Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation. 2020 , 94,	9
228	Interferon lambda rs368234815 C/C is associated with higher CD4:CD8 T-cell ratio in treated HIV-1 infection. 2020 , 17, 13	1
227	Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals. 2020 , 21,	8
226	Ginsenoside Rg3 inhibits grass carp reovirus replication in grass carp ovarian epithelial cells. 2020 , 144, 104174	0
225	Innate Immunity in Hepatitis C Virus Infection. 2021 , 11,	6
224	Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. 2021 , 37, 184-188	1

223	Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity. 2021 , 37, 46-58	23
222	Germline genetic factors influence the outcome of interferon- β therapy in polycythemia vera. 2021 , 137, 387-391	5
221	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. 2021 , 41, 133-149	1
220	Genetic susceptibility to congenital Zika syndrome: Current research and future perspectives. 2021 , 235-244	
219	Cytokines in Innate Immunity. 2021 ,	
218	IFN: Jekyll and Hyde. 2021 , 137, 291-293	
217	Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study. 2021 , 21, 102	1
216	Role of NLRs in the Regulation of Type I Interferon Signaling, Host Defense and Tolerance to Inflammation. 2021 , 22,	5
215	Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection. 2021 , 13, 109-119	0
214	Herpesviruses and the Type III Interferon System. 2021 , 36, 577-587	5
213	Life-Threatening Influenza, Hemophagocytic Lymphohistiocytosis and Probable Vaccine-Strain Varicella in a Novel Case of Homozygous Deficiency. 2020 , 11, 624415	8
212	Broad-Spectrum Robust Direct Bactericidal Activity of Fish IFN β Reveals an Antimicrobial Peptide-like Function for Type I IFNs in Vertebrates. 2021 , 206, 1337-1347	11
211	Advances in Hepatitis E Virus Biology and Pathogenesis. 2021 , 13,	6
210	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. 2021 , 56, 304-311	
209	Proteomic Analysis of ISGylation in Immortalized Porcine Alveolar Macrophage Cell Lines Induced by Type I Interferon. 2021 , 9,	2
208	Interferon- β rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population. 2021 , 166, 1047-1056	0
207	An interferon lambda 4-associated variant in the hepatitis C virus RNA polymerase affects viral replication in infected cells. 2021 , 102,	2
206	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. 6, 47	0

205	Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients. 2021,	6
204	Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling. 2021, 22,	1
203	IFNL4 genetic variant can predispose to COVID-19.	3
202	IL28B????????????(1)????????(GWAS). 2021, 62, 206-208	
201	Interferon lambda in inflammation and autoimmune rheumatic diseases. 2021, 17, 349-362	9
200	IFN- λ is associated with increased risk and earlier occurrence of several common infections in African children. 2021, 22, 44-55	2
199	IFN- λ genetic variants influence clinical malaria episodes in a cohort of Kenyan children. 2021, 20, 196	1
198	Interferon- β Gene Polymorphic Variants, rs4803217 and rs12980275, Responsiveness to HBV Vaccine and Outcome of HBV and HCV Exposure in Hemodialyzed Patients. 2021, 21,	
197	Biochemical, molecular genetic and clinical aspects of COVID-2019. 2021, 20, 147-157	1
196	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. 2021, 9, 498-510	89
195	IFN- λ therapy prevents severe gastrointestinal graft-versus-host disease. 2021, 138, 722-737	12
194	Absence of interferon- λ enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. 2021, 56, 855-861	
193	Critical role of interferons in gastrointestinal injury repair. 2021, 12, 2624	13
192	IFNL4 rs12979860 polymorphism influences HBV DNA viral loads but not the outcome of HBV infection in Moroccan patients. 2021, 23, 104802	1
191	SNPs of the IFNL favour spontaneous clearance of HCV infection in children. 2021,	0
190	Immune Inflammation Pathways as Therapeutic Targets to Reduce Lethal Prostate Cancer in African American Men. 2021, 13,	3
189	Genomic Analyses of the Metastasis-derived LNCaP, VCaP, and PC3-AR Prostate Cancer Cell Lines.	0
188	Interferon Lambda 3/4 (IFN λ 3/4) rs12979860 Polymorphisms Is Not Associated With Susceptibility to Systemic Lupus Erythematosus, Although It Regulates OASL Expression in Patients With SLE. 2021, 12, 647487	1

187	Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. 2021 , 13,	2
186	Presence of interferon- λ , male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. 2021 , 56, 849-854	1
185	Functional genetic variants of the IFN- β (IL28B) gene and transcription factor interactions on its promoter. 2021 , 142, 155491	0
184	A novel anti-influenza combined therapy assessed by single cell RNA-sequencing.	0
183	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. 2021 , 139, 111642	19
182	The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations. 2021 , 12, 717540	1
181	Role of Alternative Splicing in Regulating Host Response to Viral Infection. 2021 , 10,	2
180	Hepatic Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology. 2021 , 22,	0
179	Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha. 2021 , 11, 656393	1
178	RNA regulatory mechanisms that control antiviral innate immunity. 2021 , 304, 77-96	5
177	Paraoxonase 1 gene (PON1) variants concerning hepatitis C virus (HCV) spontaneous clearance in hemodialysis individuals: a case-control study. 2021 , 21, 875	
176	Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. 2021 , 12, 4882	2
175	Interplay between Hepatitis E Virus and Host Cell Pattern Recognition Receptors. 2021 , 22,	1
174	Intracellular Accumulation of IFN- λ Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects. 2021 , 12, 692263	1
173	Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. 2021 , 29, 100909	
172	A 584bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. 2021 , 108, 1852-1865	1
171	Conserved induction of distinct antiviral signalling kinetics by primate interferon lambda 4 proteins.	
170	A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients. 2021 , 12, 709388	1

169	Sex Hormones and Aging Modulate Interferon Lambda 1 Production and Signaling by Human Uterine Epithelial Cells and Fibroblasts. 2021 , 12, 718380	1
168	Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?. 2021 , 50, 119-127	10
167	Immunological lessons from genome-wide association studies of infections. 2021 , 72, 87-93	2
166	Human host genetics and susceptibility to ZIKV infection. 2021 , 95, 105066	2
165	Novel variant in glycoprotein c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. 2021 , 143, 112195	0
164	Interferons. 2021 , 447-452	0
163	Interferon signaling. 214-225	1
162	Natural History of Chronic Hepatitis C. 2016 , 3-55	1
161	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. 2020 , 28, 1333-1352	11
160	An overview of cancer health disparities: new approaches and insights and why they matter. 2021 , 42, 2-13	11
159	IFN- λ desensitizes the response to IFN- α treatment in chronic hepatitis C through long-term induction of USP18. 2016 , 97, 2210-2220	16
158	Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?. 2016 , 97, 2592-2598	2
157	Cross-species antiviral activity of goose interferon lambda against duck plague virus is related to its positive self-regulatory feedback loop. 2017 , 98, 1455-1466	5
156	IFN- λ is associated with increased risk and earlier occurrence of gastrointestinal, respiratory and malarial infections in Malian children.	1
155	Negative regulation of ACE2 by interferons in vivo and its genetic control.	3
154	Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2. 2020 ,	14
153	Emerging concepts in immunity to hepatitis C virus infection. 2013 , 123, 4121-30	73
152	KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. 2013 , 8, e83381	15

151	IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan. 2014 , 9, e93011	8
150	Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. 2014 , 9, e112592	17
149	Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. 2015 , 10, e0136227	12
148	Hepatic Interferon- β (IFNL3) Gene Expression Reveals Not to Be Attenuated in Non-Favorable IFNL3 rs4803217 or IFNL4 rs368234815 Minor Allele Carriers in Chronic Hepatitis C. 2015 , 10, e0143783	2
147	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. 2015 , 10, e0145105	4
146	Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. 2016 , 11, e0146258	23
145	Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. 2016 , 11, e0166036	7
144	Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C. 2016 , 11, e0166998	5
143	Integrated modeling and analysis of intracellular and intercellular mechanisms in shaping the interferon response to viral infection. 2017 , 12, e0186105	4
142	Hepatitis E virus persists in the presence of a type III interferon response. 2017 , 13, e1006417	48
141	Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. 2016 , 4, 26-31	1
140	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. 2016 , 7, 37487-37497	15
139	Inflammatory bowel disease pathobiology: the role of the interferon signature. 2020 , 33, 125-133	16
138	Genetic Polymorphisms within Interferon- λ Region and Interferon- β in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. 2019 , 26, 4832-4851	2
137	Innate and Adaptive Immune Responses in Chronic HCV Infection. 2017 , 18, 826-843	31
136	Overview of Interferon: Characteristics, signaling and anti-cancer effect. 2017 , 1, 001-016	10
135	Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. 2013 , 19, 7055-61	6
134	Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. 2013 , 19, 7852-66	7

133	Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. 2013 , 19, 8940-8	29
132	Immunologic, metabolic and genetic factors in hepatitis C virus infection. 2014 , 20, 3443-56	26
131	Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. 2014 , 20, 9245-52	7
130	Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. 2014 , 20, 17830-8	8
129	Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. 2015 , 21, 5496-504	7
128	Hepatitis C virus infection: Are there still specific problems with genotype 3?. 2015 , 21, 12101-13	15
127	The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. 2016 , 21, 72	10
126	IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. 2013 , 5, 635-41	2
125	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. 2014 , 6, 759-65	3
124	Role of IL28B genotype in older hepatitis C virus-infected patients. 2013 , 3, 54	3
123	Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. 2015 , 4, 178-84	3
122	The IFN- λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. 2014 , 14, e15076	7
121	Interferon- λ Genetic Variations and Hepatitis C: Yet to be Discovered. 2014 , 14, e19433	3
120	The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection. 2016 , 16, e34266	12
119	The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy. 2017 , 17,	1
118	Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B. 2015 , 16, 5515-9	6
117	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. 2019 , 8,	17
116	Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. 2019 , 8,	9

- 115 Pathogenesis and virulence of herpes simplex virus. **2021**, 12, 2670-2702 6
- 114 ADAR Editing in Viruses: An Evolutionary Force to Reckon with. **2021**, 13, 4
- 113 IFNL4 genetic variant can predispose to COVID-19. **2021**, 11, 21185 6
- 112 Differential roles of interferons in innate responses to mucosal viral infections. **2021**, 42, 1009-1023 4
- 111 Chronic Hepatitis C. **2022**, 163-201
- 110 Murine Type III interferons are functionally redundant and correlate with bacterial burden during influenza/bacterial super-infection. **2021**, 16, e0255309 1
- 109 Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases. **2021**, 12, 767505 1
- 108 Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. **2013**, 1, 39-44 3
- 107 Discovery and Characterization of Cancer Genetic Susceptibility Alleles. **2014**, 309-321.e3
- 106 Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response. **2014**, 60, 568-575
- 105 Treatment of chronic hepatitis C recent development and future perspective. **2014**, 55, 8-14 2
- 104 Epidemiological Differences of Chronic Viral Hepatitis C in Caucasian and Asian Races Taking into Account Population Interferon Gene Polymorphism. **2015**, 14, 31-36
- 103 Innate Immune Recognition of Hepatitis C Virus. **2016**, 299-329
- 102 Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy. **2016**, 303-321
- 101 Human Susceptibility and Response to Viral Diseases. 567-578
- 100 Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis. **2017**, 927-955 1
- 99 Basic Immunobiology. **2017**, 1-93
- 98  **2017**, 1254-1266

- 97 Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.
- 96 A Polymorphic Residue That Attenuates the Antiviral Potential of Interferon Lambda 4 in Hominid Lineages. 1
- 95 A Polymorphic Residue That Attenuates Interferon Lambda 4 Activity in Hominid Lineages.
- 94 Molecular and Genetics-Based Diagnostics. **2018**, 127-135.e2
- 93 Interferon lambda 4 impacts broadly on hepatitis C virus diversity.
- 92 Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes.
- 91 What makes the hepatitis C virus evolve?. **2019**, 8, 0
- 90 An interferon lambda 4-associated variant in the hepatitis C virus RNA polymerase affects viral replication in infected cells.
- 89 Interferon Lambda Regulates Cellular and Humoral Immunity in Pristane-Induced Lupus. **2021**, 22, 0
- 88 The role of type III interferons in systemic autoimmune diseases. **2022**, 199-212
- 87 Large scale genome-wide association study in a Japanese population identified 45 novel susceptibility loci for 22 diseases. 2
- 86 Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. **2021**, 101522 5
- 85 IFN- λ may contribute to HCV persistence by increasing ER stress and enhancing IRF1 signaling.
- 84 Comparative genomic analysis of eutherian interferon genes. **2020**, 112, 4749-4759 0
- 83 Interferon lambda 4 can directly activate human CD19 B cells and CD8 T cells. **2021**, 4, 3
- 82 Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. **2014**, 33, 177-83 2
- 81 The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection. **2018**, 19, 2191-2197
- 80 Preparation and Characterization of PLGA Nanoparticles Containing Plasmid DNA Encoding Human IFN-lambda-1/IL-29. **2019**, 18, 156-167 6

79	Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients. 2021 , 167, 153	0
78	A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. 2021 , 14, 1505-1515	1
77	Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 Proteins. 2021 , 12, 772588	0
76	Type III Interferons: Emerging Roles in Autoimmunity.. 2021 , 12, 764062	1
75	The Impact of IFN λ on the Adaptive Immune Response to SARS-CoV-2 Infection. 2021 , 41, 407-414	0
74	De novo developed protein binders mimicking Interferon lambda signaling. 2021 ,	1
73	Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1.. 2021 , 12, 764746	2
72	Modeling Innate Antiviral Immunity in Physiological Context. 2021 , 167374	1
71	Type I interferons: One stone to concurrently kill two birds, viral infections and cancers. 2021 , 2, 100014	0
70	Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions.. 2022 , 208, 247-256	3
69	Competitive Endogenous RNA Network Activates Host Immune Response in SARS-CoV-2-, panH1N1 (A/California/07/2009)-, and H7N9 (A/Shanghai/1/2013)-Infected Cells.. 2022 , 11,	0
68	Antiviral Toll-like Receptor Signaling in Non-Parenchymal Liver Cells Is Restricted to TLR3.. 2022 , 14,	0
67	Interferon lambda signals in maternal tissues to exert protective and pathologic effects in a gestational-stage dependent manner.	0
66	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQ α 1.. 2022 ,	0
65	Distinct molecular phenotypes involving several human diseases are induced by IFN- β and IFN- δ in monocyte-derived macrophages.. 2022 ,	
64	Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.. 2022 ,	1
63	Distribution of Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19.. 2022 , 10,	1
62	Pathophysiology of Chronic Liver Disease Development.. 2022 , 23,	

- 61 Type III interferons induce pyroptosis in gut epithelial cells and delay tissue restitution upon acute intestinal injury. o
- 60 Variants in Interferon Lambda are Associated with Very Early Onset Inflammatory Bowel Disease.
- 59 Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.. **2022**, o
- 58 Pegylated-interferon- α treatment-induced peripheral interferon stimulated genes are associated with SARS-CoV-2 viral load decline despite delayed T cell response in older individuals.
- 57 IFNL4 rs368234815 polymorphism does not predict risk of BK virus associated nephropathy after living-donor kidney transplant: A case-control study.. **2022**, e14663
- 56 Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.. **2021**, e24290
- 55 Image_1.jpeg. **2019**,
- 54 Image_2.jpeg. **2019**,
- 53 Table_1.docx. **2019**,
- 52 Table_2.docx. **2019**,
- 51 Table_3.docx. **2019**,
- 50 Table_4.docx. **2019**,
- 49 Table_5.docx. **2019**,
- 48 Table_1.doc. **2019**,
- 47 Table_2.doc. **2019**,
- 46 Table_3.doc. **2019**,
- 45 Table_4.doc. **2019**,
- 44 Table_5.doc. **2019**,

- 43 Table_6.doc. **2019**,
- 42 Table_7.doc. **2019**,
- 41 Human herpesvirus 8 infection is associated with prostate cancer among IFNL4- Δ carriers.. **2022**, 0
- 40 Interferon Lambda Signals in Maternal Tissues to Exert Protective and Pathogenic Effects in a Gestational Stage-Dependent Manner.. **2022**, e0385721 1
- 39 genotype influences the rate of HIV-1 seroconversion in men who have sex with men.. **2022**, 13, 757-763
- 38 Genetic polymorphisms in the , , and genes were associated with biochemical index of chronic HBV patients from Yunnan, China.. **2022**, 10, e13353 0
- 37 The role of IFNL4 in liver inflammation and progression of fibrosis.. **2022**, 1
- 36 A human and rhesus macaque interferon-stimulated gene screen reveals ARHGEF3/XPLN as an antiviral gene against hepatitis C virus and other flaviviruses.
- 35 The presence of interferon affects the progression of non-alcoholic fatty liver disease. 0
- 34 A Game of Infection [Song of Respiratory Viruses and Interferons. 12,
- 33 A Human and Rhesus Macaque Interferon-Stimulated Gene Screen Shows That Over-Expression of ARHGEF3/XPLN Inhibits Replication of Hepatitis C Virus and Other Flavivirids. **2022**, 14, 1655 0
- 32 The gamble between oncolytic virus therapy and IFN. 13, 0
- 31 Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study.
- 30 A Conversation with Dr. Ludmila Prokunina-Olsson. **2022**, 42, 462-466 0
- 29 Macrophages and neutrophils express IFN β in granulomas from Mycobacterium tuberculosis-infected nonhuman primates. 13, 0
- 28 Semantic and population analysis of the genetic targets related to COVID-19 and its association with genes and diseases. 0
- 27 When does hepatitis B virus meet long-stranded noncoding RNAs?. 13, 0
- 26 Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection. 0

25	The Influenza-Induced Pulmonary Inflammatory Exudate in Susceptible Tpl2-Deficient Mice Is Dictated by Type I IFN Signaling.	0
24	An anti-influenza combined therapy assessed by single cell RNA-sequencing. 2022 , 5,	0
23	Comparison of HAV and HCV infections <i>in vivo</i> and <i>in vitro</i> reveals distinct patterns of innate immune evasion and activation.	0
22	Interferon- β treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. 2022 , 13,	2
21	Enhanced TLR3 responsiveness in hepatitis C virus resistant women from the Irish anti-D cohort. 2022 , 3, 100804	0
20	Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. 2022 , 14, 2490	1
19	Emerging Role of Interferon-Induced Noncoding RNA in Innate Antiviral Immunity. 2022 , 14, 2607	0
18	Interleukin-29 Accelerates Vascular Calcification via JAK2/STAT3/BMP2 Signaling.	0
17	No Association of IFNL4 Genotype With Opportunistic Infections and Cancers Among Men With Human Immunodeficiency Virus 1 Infection.	0
16	Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 Genes Are Associated with Worse Clinical Outcomes in COVID-19. 2023 , 14, 29	2
15	Interferon Family Cytokines in Obesity and Insulin Sensitivity. 2022 , 11, 4041	0
14	Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study. 12,	1
13	IFNL3/4 polymorphisms as a two-edged sword: An association with COVID-19 outcome. 2023 , 95,	0
12	Pathogenesis and treatment of Sjogren's syndrome: Review and update. 14,	0
11	The Complexity of Interferon Signaling in Host Defense against Protozoan Parasite Infection. 2023 , 12, 319	0
10	Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. 2023 , 11, 480	0
9	IFN- β s protective against lethal oral <i>Toxoplasma gondii</i> infection.	0
8	Influence of IL-28B serum level and gene polymorphism in a sample of Iraqi patients with ankylosing spondylitis. 64-73	0

- 7 IMPACT OF GENETIC ANCESTRY ON THE DISTRIBUTION OF INTERFERON- λ RS12979860 POLYMORPHISM IN A GLOBAL POPULATION OF BUENOS AIRES, ARGENTINA. **2022**, 33, 19-25
- 6 A Novel Inactive Isoform with a Restored Reading Frame Is Expressed from the Human Interferon Lambda 4 TT Allele at rs368234815.
- 5 Studying T Cell Responses to Hepatotropic Viruses in the Liver Microenvironment. **2023**, 11, 681
- 4 Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
- 3 Promising hepatoprotective agents from the natural sources: a study of scientific evidence. **2023**, 13,
- 2 Current Landscape of IFN- λ Induction, Inhibition, and Potential Clinical Applications to Treat Respiratory Viral Infections. **2023**, 7, 265-272
- 1 PD-L1 and PD-L2 Immune Checkpoint Protein Induction by Type III Interferon in Non-Small Cell Lung Cancer Cells. **2023**, 152389